Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970773 | 0.86 | BCHE (0.50) | ERN1SMN1; SMN2MAPTL3MBTL1BCHE | |
| SCHEMBL31562616 | 0.83 | BCHE (0.48) | ERN1SMN1; SMN2MAPTL3MBTL1LMNA | |
| SCHEMBL31562251 | 0.81 | LIPE (0.49) | ERN1SMN1; SMN2MAPTL3MBTL1HPGD | |
| SCHEMBL21823620 | 0.81 | ERN1 (0.57) | ERN1SMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL7746131 | 0.81 | BCHE (0.48) | ERN1SMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL28496730 | 0.79 | PTPN1 (0.50) | SMN1; SMN2MAPTALDH1A1L3MBTL1LMNA | |
| SCHEMBL4883017 | 0.79 | HTR1A (0.55) | SMN1; SMN2MAPTALDH1A1L3MBTL1LMNA | |
| SCHEMBL31663469 | 0.78 | ERN1 (0.66) | ERN1SMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL4374159 | 0.78 | ERN1 (0.66) | ERN1SMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL8032642 | 0.77 | BCHE (0.50) | ERN1L3MBTL1BCHEHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20090215908-A1 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2009-08-27 | — | — | US | disclosed |
| US-20090048446-A1 | Process For Producing Benzo[C]Phenanthridine Derivative | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-0947514-B1 | NOVEL PHENANETHRIDINIUM DERIVATIVES | NIPPON KAYAKU KK (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-6187783-B1 | ANTITUMOR AGENTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0947514-A1 | NOVEL PHENANETHRIDINIUM DERIVATIVES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-10-06 | — | — | EP | disclosed |
| EP-0487930-B1 | Benzo[C]phenanthridinium derivatives | NIPPON KAYAKU KK (JP) | 1999-03-24 | — | — | EP | disclosed |
| US-5747502-A | ANTITUMOR AGENTS, ANTIGROWTH AGENTS AND ANTICARCINOGENIC AGENTS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0487930-A1 | Process for preparing benzo[C]phenanthridinium derivatives, and novel compounds prepared by said process | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | ERN1 1389/4885SMN1; SMN2 2895/4885MAPT 3329/4885 |
| US-20090215908-A1 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST | TLR4, TLR5, TLR1 | ERN1 2109/4885SMN1; SMN2 3760/4885MAPT 3117/4885 |
| US-20090048446-A1 | Process For Producing Benzo[C]Phenanthridine Derivative | CBR1, CYP1A1, CBR3 | ERN1 1109/4885SMN1; SMN2 2623/4885MAPT 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.